Our ambition : regenerate and cure
A multidisciplinary team that pools its skills to pave the way for success.
Executive Committee
Matthieu
DE KALBERMATTEN
CEO
...
20 years of experience in executive management, corporate strategy, business development and sales, for medtech company and large multinationals.
Ibon
GARITAONANDIA
CSO
...
15 years of experience in stem cell research and regenerative medicine, including Translational Research at a Californian clinical stage biotechnology company developing stem cell-based therapies
Didier
HAGUENAUER
CMODSO
...
Olivier
FRIEDRICH
CFO
...
15 years of experience in corporate finance, internal control, accounting and tax matters. Senior Manager at EY leading legal financial audits as well as due diligence transactions. CFO of a listed company on Euronext
Jean-Olivier
HIRSCH
COO
...
15 years of experience in the pharmaceutical industry, as director of pharmaceutical affairs, head of quality management and qualified person.
Scientific advisors
Cellprothera relies on the expertise of international key opinion leaders for its development, among which the members of EXCELLENT Trial Steering Committee *
Pr Deepak BHATT*
Harvard Medical Business School Boston MA, USA
Pr Cesario Borlongan
Center of excellence for aging and brain repair, University of South Florida Tampa, USA
Emeritus Professor Jeanne Loring
The Scripps Research Institute,
La Jolla CA, USA
Pr Pierre-Yves MARIE*
Brabois Universtiy Hospital Nancy, Lorraine University, France
Pr Gilles MONTALESCOT*
Pitié-Salpétrière Hospital, University Hospital Paris, France
Pr Guilio POMPILIO
Monzino Cardiology Center, University hospital Milano, Italy
Pr Jérôme RONCALLI*
Rangueil Universtiy Hospital Toulouse, France
Pr Denis-Claude ROY
University Hospital Montreal, Canada
Pr Scott SOLOMON*
Harvard Medical Business School Boston MA, USA
Pr Faiez ZANNAD*
Brabois Universtiy Hospital Nancy, Lorraine University, France
Founders
The good results of the Proof of Concept Trial led both Philippe HENON and Jean-Claude JELSCH to found CellProthera in 2008 whose objectives are to develop and bring to patients this innovative therapeutic solution.
At the origin of the therapeutic solution, Prof. Philippe HENON, MD – Head of the Hematology Department – Mulhouse Hospitals, is one of the pioneers in the field of peripheral blood stem cell (PBSC) identification and transplantation and performed the 6th peripheral blood stem cell transplantation in the world in 1986…
...
He is member of twelve national and international scientific societies and corresponding member of the New York Academy of Sciences. As the founder of the “Institut de Recherche en Hématologie et Transplantation” (IRHT) in Mulhouse, he led a research program on stemcells and discovered that CD34+ cells could regenerate the heart after a severe myocardial infarct.
He is now chairman of the Supervisory Board and Scientific Advisor.
Jean-Claude JELSCH (†2022) was for over 30 years, an esteemed member of ADECCO top management. After he co-founded Cardinal Development, a capital development company in Alsace, he became Chairman of IRHT…
...
Jean-Claude JELSCH as CEO from 2008 to 2016 has consolidated the company by successful fundraisings and led development programs by partnering with industrial companies.
QMS & Regulatory Affairs
As a health care startup, the quality of our data and results depends on an efficient Quality Management System in compliance with the guidelines and standards relevant to our activities. The objective of our QMS is the quality, safety, efficiency and performance entrusted to our products.
The commitment of the Executive Committee and our Quality Policy guide our activities according to 3 axes:
– Ensure a high level of quality on our processes, products and services for the safety of the patient. This is achieved by implementing a continuous improvement system.
– Involve the entire company in our objectives, costs and deadlines by making individuals responsible for their activities and projects.
– Set up a management system allowing the cohesion of the teams by the definition of common values.
Our status as a pharmaceutical establishment authorized and inspected by the ANSM (GMP certificate below), allows us to manufacture and certify an Advanced Therapy Medicinal Product resulting from tissue engineering. This ATMP is undergoing a Phase I/IIb clinical trial. The design and development of our cell culture and expansion platform is recognized by the British Standards Institution through our ISO 13485: 2016 certification (see below).
